Precuroxè un integratore composto da prodotti naturali erettogeni selezionati tra i migliori presenti in naturain grado di simulare le azioni dei farmaci per la erezione.
Di recente registrazione ministeriale , (Marzo 2014) , prodotto in Italia per rispondere all' esigenze dei consumatori di coniugare prezzo, prestazione e qualità di un prodotto.
Grazie ai suoi componenti, Precurox è un integratore versatile che può essere utilizzato come coadiuvante ai trattamenti, della astenia sessuale (arginina ad alti dosaggi) , del deficit erettile (arginina + tribulus+gincko), della infertilità (arginina +propionil carnitina + nicotinamide ). Praticamente un unico integratore per rispondere a tanti problemi.
Le sostanze presenti in Precurox , sono un mix selezionato e dotato di una fisiologica coadiuvante azione rinvigorente la funzione erettiva.
E' inoltre utilizzato come coadiuvante ai trattamenti delle forme di astenia e di stanchezza cronica sia fisica che mentale, nel recupero di stress psicofisici postoperatori, nel recupero del deficit erettile dopo prostatectomia radicale.
Contienearginina ad alti dosaggi (2,5 grammi per bustina ). L'arginina è il precursore dell'ossido nitrico, la sostanza (gas) che viene consumata durante l'erezione. l'ossido nitrico rilascia la muscolatura liscia dei vasi dei copri cavernosi consentendo una vasodilatazione continua in grado di aumentare il flusso sanguigno penieno ed erezioni potenti e di lunga durata.
Precurox può essere utilizzato da solo o come coadiuvante ai trattamenti mirati al benessere fisiologico della attivita erettile erettile compromessa dallo stress, dalla fatica, dalla depressione, dall'ansia da prestazione, diabete....
Precurox grazie al ginko biloba 75 mg edal tribulus terrestre 250 mg a dosaggi ottimali aumenta il desiderio sessuale e permette di migliorare le funzioni vascolari alla base della fisiologica erezione già dalle prime assunzioni. Il tempo di azione e l’efficacia della bustina possono variare da persona a persona.
La qualità degli ingredienti di Precurox , tutti naturali, e la loro miscelazione studiata e validata da numerosi studi scientifici , garantiscono la assenza di effetti collaterali e la massinm sicurezza.
Precurox si trova on line su siti autorizzati o in farmacia.
Acta Biomed.2014 Dec 17;85(3):222-8.
L-Arginine and vascular diseases: lights and pitfalls!
Calabrò RS1,Gervasi G,Bramanti P.
L-Arginine, a semi-essential cationic amino acid involved in multiple areas of human physiology and metabolism, is a precursor of nitric oxide, and, recently, it has been found to crucially influence endothelial function.Arginineappears to be safe and effective therapy for many health conditions, particularly vascular diseases responsive to modulation of endothelial-derived relaxing factor including intermittent claudication, angina pectoris anderectile dysfunction. However, L-argininemetabolism is still not fully understood, highlighting a complex implication for its pharmacological use in clinical practice. In this review, we want to point out the lights and pitfalls of L-arginineas potential therapeutic option in vascular disorders.
Expert Opin Emerg Drugs. 2015 Mar 5:1-13. [Epub ahead of print]
Emerging drugs for the treatment of erectile dysfunction.
Peak TC1, Yafi FA, Sangkum P, Hellstrom WJ.
Introduction: Erectile dysfunction adversely affects the lives of millions of men, and is the most commonly treated sexual disorder today. Theerectile process has been extensively investigated, with major advances made in elucidating many of the complex molecular pathways involved. These advances have allowed researchers to design and study drug formulations that target various aspects of this complex process. The initial culmination of this research was the introduction of phosphodiesterase 5-inhibitors. While effective in many patients, they are not satisfactory for all afflicted men. As a result, researchers are developing novel drugs that target different molecular pathways. Areas covered: The paper will review these pathways, and the potential agents that target them. More specifically, first dopaminergic and melanocortin receptor agonists that act centrally will be covered. Then, the paper will examine the "second-generation" phosphodiesterase 5-inhibitors, soluble guanylate cyclases, rho-kinase inhibitors, and maxi-k channel activators that act peripherally. Expert opinion: Most of these novel drugs have yet to reach Phase III studies. However, it is likely that in years to come, patients will be selectively treated with these novel agents as a monotherapy or in combination with others acting in a synergistic manner.
New approaches to the design and discovery of therapies to prevent erectile dysfunction.
Toque HA1,Caldwell RW.
Nitric oxide (NO) is critically involved in erectile function. Since NO synthase (NOS) and arginase compete for the same substrate l-arginine, limiting arginase activity may provide more NO and thus be a beneficial therapeutic approach to erectile dysfunction (ED). In the corpora cavernosa, excessive arginase activity/expression has been implicated through studies of preclinical and clinical models of ED. Further, the inhibition of arginase has shown to increase vascular system relaxation and enhance blood flow in penile circulation. Further studies, therefore, looking at therapies targeting arginase could prove to be clinically useful.
The authors review gene- and cell-based therapies, the involvement of RhoA/Rho-kinase (ROCK), MAPK and arginase in ED.
Extensive literature supports the view that upregulated arginase activity in cavernosal tissue can reduce NOS function and NO production. Excessive arginase activity has been shown to contribute to the progression of aging-, hypertension- and diabetes-induced vasculardysfunction as well as ED. Earlier studies have shown that RhoA/ROCK and subsequent activation of p38 MAPK mediate elevation of arginase expression/activity in diabetic and hypertensive mice. Reducing corporal arginase activity by gene-based or pharmacological therapy and/or inhibition of upstream regulators of arginase expression may provide novel therapeutic approaches in the management of ED.
Andrology.2013 Mar;1(2):223-8. doi: 10.1111/j.2047-2927.2012.00046.x. Epub 2012 Dec 26.
A randomized, double-blind, crossover, placebo-controlled comparative clinical trial of arginine aspartate plus adenosine monophosphate for the intermittent treatment of male erectile dysfunction.
Neuzillet Y1,Hupertan V,Cour F,Botto H,Lebret T.
Efficacy and safety of l-arginine aspartate 8 g combined with 200 mg of adenosine monophosphate (AA) with placebo (PL) alone for intermittent treatment of mild-to-moderate erectile dysfunction (ED) were compared. The study design was a double-blind, PL-controlled, two-way crossover randomized clinical trial with 26 patients. Efficacy was assessed by International Index of Erectile Function (IIEF) and two additional validated questionnaires [the Erection Hardness Score (EHS) and the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS). During each crossover period, separated by a 2-week wash-out period, drugs were administered orally, 1-2 h before sexual intercourse. Primary endpoint was a change in the IIEF. Secondary endpoints were patient and investigator assessments of treatment success. Investigators' and patients' assessment of efficacy was significantly improved by the combination vs. PL (p = 0.01 and p = 0.04 respectively]. EHS and EDITS questionnaires were both improved by the combination (p = 0.015 and p = 0.017 respectively). There was no significant difference in terms of tolerance between AA and PL or severe adverse events. ED patients demonstrated significant improvements in all IIEF domains with the exception of the Sexual Desire and Orgasmic Domains when treated with AA compared with PL. This pilot phase II study showed that the on-demand oral administration at a high dosage of l-arginine aspartate-adenosine monophosphate combination may be effective in patients with mild-to-moderate ED, is very well tolerated and could be tested as a safe first-line therapy in a larger size phase III study.
Bibliografia recente su Gincko biloba e disfunzione erettile
Urology.2015 May;85(5):1214.e7-1214.e15. doi: 10.1016/j.urology.2015.01.026. Epub 2015 Mar 13.
Effect of Ginkgo biloba Extract (EGb-761) on Recovery of Erectile Dysfunction in Bilateral Cavernous Nerve Injury Rat Model.
Wu YN1,Liao CH2,Chen KC3,Liu SP4,Chiang HS5.
To investigate whether the therapeutic effect of Ginkgo biloba extract (GBE) in a rat model can improveerectile dysfunctionafter bilateral cavernous nerve injury.
Forty-three male Sprague-Dawley rats underwent cavernous nerve crush injury and were randomized into 4 groups, including: vehicle only, high-dose GBE, medium-dose GBE, and low-dose GBE. Eight animals underwent sham operation. Four weeks later,erectilefunction was assessed by cavernous nerve electrostimulation, and penile tissue was collected for histologic analysis.
Significant recovery oferectilefunction was observed in the high-dose GBE group in a dose-dependent manner as compared with the vehicle-only group (P <.001). The high-dose GBE group had a significant increase in neurofilament-1 expression (P <.001), preservation of neural nitric oxide synthase nerve fibers of the dorsal penile nerve (P <.05), and increased smooth muscle cell content (P <.001) compared with the vehicle-only group. In addition, high-dose GBE markedly augments the smooth muscle-to-collagen ratio (P <.05) and reduces the apoptotic index.
Administration of GBE increases neuron survival and preserves the neural nitric oxide synthase nerve fiber and contents of the corpus cavernosum after bilateral cavernous nerve injury. These implications indicate the beneficial effects of GBE use in the repair of the cavernous nerve and recovery oferectilefunction after radical prostatectomy.
Dietary supplements and nutraceuticals in the management
of andrologic disorders.
Tamler R, Mechanick JI.
Endocrinol Metab Clin North Am.
2007 Jun;36(2):533-52. Review.
PMID: 17543734 [PubMed - indexed for MEDLINE]
Dietary supplements and nutraceuticals are commonly used by men witherectile dysfunction, decreased libido, BPH, and concerns about developing prostate cancer. Many preparations do not contain the advertised dosages of the active ingredient or are contaminated. Dietary supplements and nutraceuticals, particularly those addressingerectile dysfunctionand libido, need to undergo rigorous testing before they can be wholeheartedly recommended.
Strategies for managing antidepressant-induced sexual
dysfunction: a review.
Curr Psychiatry Rep. 2006
PMID: 17094922 [PubMed - indexed for MEDLINE]
Sexualdysfunctionis a common side effect of most antidepressants. Lower rates are reported with some newer agents such as reboxetine and bupropion. The evidence base for its management is limited but growing, with most approaches only tested in a small number of trials. Available strategies include watchful waiting, the use of short drug holidays, and a change of antidepressant. Many specific antidotes have been trialed but with lack of convincing benefit in most cases. However, where antidepressants causeerectile dysfunction, the use of sildenafil has the largest and most consistent evidence base.
Triple-blind, placebo-controlled trial of Ginkgo biloba in
sexual dysfunction due to antidepressant drugs.
Hum Psychopharmacol. 2004
PMID: 15378664 [PubMed - indexed for MEDLINE]
A triple-blind (investigator, patient, statistician), randomized, placebo-controlled, trial of Ginkgo biloba 240 mg daily was carried out. Following a 1-week control, it was given to 24 patients with sexual impairment due to antidepressant drugs. Efficacy analysis was carried out on eight males and five females on placebo and six males and five females on Ginkgo, completing the full 12 weeks of treatment. Not included were three subjects who dropped out after 6 weeks. A validated, sex (gender)-orientated questionnaire was recorded at - 1, 0, 1, 3, 6, 9 and 12 weeks, and a non-blind follow-up for a further 6-weeks on Ginkgo. Hamilton anxiety and depression ratings were made at 0, 6 and 12 weeks and simple global assessments of alertness and memory. There were some spectacular individual responses in both groups, but no statistically significant differences, and no differences in side-effects.
2004 John Wiley & Sons, Ltd.
Prevention and treatment of erectile dysfunction using
lifestyle changes and dietary supplements: what works and what is worthless,
Moyad MA, Barada JH, Lue TF, Mulhall JP, Goldstein I,
Fawzy A; Sexual Medicine Society Nutraceutical Committee.
Urol Clin North Am. 2004
PMID: 15123406 [PubMed - indexed for MEDLINE]
It seems naïve to believe that some plants or herbs do not contain specific compounds that could benefit patients with ED. Many supplements have not been investigated in a laboratory or clinical research setting before commercial sale, however,which creates a complex situation. If efficacy is or is not demonstrated through adequate research, then the benefit or lack thereof cannot be mentioned on the label. Furthermore, clinicians and the public cannot be made aware of which compounds or supplements are effective because no general standards for sale exist under the current guidelines. Dietary supplements have received a tremendous amount of publicity. The large and growing market for ED treatment seems to have contributed partly to the promotion of numerous supplements and their apparent benefits. Whether these dietary supplements have merit is questionable. Some supplements may produce results opposite to those advertised. Other supplements may be enjoying the benefits of the placebo effect. Because a placebo response of 25% to 50% has been recorded in clinical trials with effective agents, it is understandable that some supplements enjoy financial success despite the limited research espousing their use. If one to two of four individuals or one of three individuals who try a dietary supplement gain some benefit for their ED, the market for these supplements will remain extraordinary. On a larger scale, of 100,000 men who try a supplement, approximately 25,000 to 50,000 will claim some success. The challenge for clinicians is to discuss the placebo response properly and the need for good research before any intervention, especially supplements, can be advocated for general use. Table 2 summarizes some popular ED supplements and general conclusions that can be drawn from clinical investigations. Some dietary supplements may have an active ingredient that benefits patients with certain types of ED. An exciting area of future dietary supplement research is the ability of certain agents to have a synergistic effect with prescription agents for ED, thereby improving response rates in men that have failed approved ED therapy initially, especially with oral agents. Randomized clinical trials are the best method of determining which dietary supplements will become a part of conventional medicine. Therefore, more randomized trials for dietary supplements are needed so that they may have the opportunity to become a part of the mainstream milieu, which means that more funding needs to be made available for ED research. The coming years of research should bring enormous excitement and objectivity to this area of medicine.
Nutrients and botanicals for erectile dysfunction:
examining the evidence.
Altern Med Rev. 2004
PMID: 15005641 [PubMed - indexed for MEDLINE] Free Article
Erectile dysfunctionaffects 50 percent of men ages 40-70 in the United States and is considered an important public health problem by the National Institutes of Health. Consumers are exposed to a plethora of natural products claiming to restore erection and sexual vitality. A review of the available empirical evidence reveals most naturally occurring compounds lack adequate clinical trials to support efficacy. However, arginine, yohimbine, Panax ginseng, Maca, and Ginkgo biloba all have some degree of evidence they may be helpful forerectile dysfunction. Improvements in penile endothelial L-arginine-nitric oxide activity appear to be a unifying explanation for the actions of these naturally occurring agents.
A placebo-controlled, double-blind trial of Ginkgo biloba
for antidepressant-induced sexual dysfunction.
Kang BJ, Lee SJ, Kim MD, Cho MJ.
Hum Psychopharmacol. 2002
PMID: 12404672 [PubMed - indexed for MEDLINE]
The aim of this study was to examine the effect of Ginkgo biloba on antidepressant-induced sexualdysfunction. The Ginkgo biloba (n=19) and the placebo groups (n=18) were divided; each to be administered with Ginkgo biloba and placebo respectively for 2 months by means of a randomized placebo-controlled, double-blind study. The results of this 2 month trial were: (1) there was no statistical significant difference from the placebo at weeks 2, 4 and 8 after medication; (2) in comparison with baseline, both the Ginkgo biloba group and the placebo group showed improvement in some part of the sexual function, which is suggestive of the importance of the placebo effect in assessing sexual function. This study did not replicate a prior positive finding supporting the use of Ginkgo biloba for antidepressant, especially SSRI, induced sexualdysfunction.
Copyright 2002 John Wiley & Sons, Ltd.
Dietary supplements and other alternative medicines for
erectile dysfunction. What do I tell my patients?
Urol Clin North Am. 2002
PMID: 12109338 [PubMed - indexed for MEDLINE]
Dietary supplements and other alternative medicines have enjoyed a tremendous amount of popularity and use over the past decade. Although, the prevalence of these therapies forerectile dysfunction(ED) is unknown at this time, numerous media outlets and alternative medicine publications seem to support the utilization of these therapies for ED. The placebo effect is approximately 25% (1 out of 4 benefit) from past randomized trials of FDA approved medications for ED. Adequate clinical trials are needed for dietary supplements for ED to access whether or not a benefit beyond a placebo effect exists. Clinicians should become aware of these supplements and the current research espousing or discouraging their use, and they should understand the adverse effects associated with them in order to effectively discuss these products with any patient inquiring about them.
Phytochemicals and the breakthrough of traditional herbs
in the management of sexual dysfunctions.
Int J Androl. 2000;23 Suppl
PMID: 10849504 [PubMed - indexed for MEDLINE]
Traditional herbs have been a revolutionary breakthrough in the management oferectile dysfunctionand have become known world-wide as an 'instant' treatment. The modern view of the management oferectile dysfunctionsubscribes to a single etiology, i.e. the mechanism of erection. A large number of pharmacological agents are orally consumed and vasoactive agents inserted intraurethrally or injected intrapenially to regain good erection. Modern phytochemicals have developed from traditional herbs. Phytochemicals focus their mechanism of healing action to the root cause, i.e. the inability to control the proper function of the whole body system. Hence phytochemicals manageerectile dysfunctionin the frame of sexualdysfunctionas a whole entity. Protodioscin is a phytochemical agent derived fromTribulusterrestris L plant, which has been clinically proven to improve sexual desire and enhance erection via the conversion of protodioscine to DHEA (De-Hydro-Epi-Androsterone). Preliminary observations suggest thatTribulusterrestris L grown on different soils does not consistently produce the active component Protodioscin. Further photochemical studies of many other herbal plants are needed to explain the inconsistent results found with other herbal plants, such as in diversities of Ginseng, Eurycoma longifolia, Pimpinella pruacen, Muara puama, Ginkgo biloba, Yohimbe etc.
Ginkgo biloba for antidepressant-induced sexual
Cohen AJ, Bartlik B.
J Sex Marital Ther. 1998
PMID: 9611693 [PubMed - indexed for MEDLINE]
In an open trial ginkgo biloba, an extract derived from the leaf of the Chinese ginkgo tree and noted for its cerebral enhancing effects, was found to be 84% effective in treating antidepressant-induced sexualdysfunctionpredominately caused by selective serotonin reuptake inhibitors (SSRIs, N = 63). Women (n = 33) were more responsive to the sexually enhancing effects of ginkgo biloba than men (N = 30), with relative success rates of 91% versus 76%. Ginkgo biloba generally had a positive effect on all 4 phases of the sexual response cycle: desire, excitement (erection and lubrication), orgasm, and resolution (afterglow). This study originated from the observation that a geriatric patient on ginkgo biloba for memory enhancement noted improved erections. Patients exhibited sexualdysfunctionsecondary to a variety of antidepressant medications including selective serotonin reuptake inhibitor (SSRIs), serotonin and nonrepinephrine reuptake inhibitor (SNRIs) monoamine oxidase inhibitor (MAOIs), and tricyclics. Dosages of ginkgo biloba extract ranged from 60 mg qd to 120 mg bid (average = 209mg/d). The common side effects were gastrointestinal disturbances, headache, and general central nervous system activation. The article includes a discussion of presumed pharmacologic mechanisms, including effects on platelet activating factor, prostaglandins, peripheral vasodilatation, and central serotonin and norepinephrine receptor factor modulation.
Ginkgo biloba for antidepressant-induced sexual dysfunction?[J Sex Marital Ther. 1999]
Caution recommended.[J Sex Marital Ther. 1999]
Bibliografia tribulus e deficit erettile
Alga Ecklonia bicyclis, Tribulus terrestris, and
glucosamine oligosaccharide improve erectile function, sexual quality of
life, and ejaculation function in patients with moderate mild-moderate
erectile dysfunction: a prospective, randomized, placebo-controlled,